TRAXENS
Traxens, a company providing high-value data and services for the supply chain industry, announces today that its patented cargo tracking IoT system will be used on CFL multimodal’s connected freight wagons throughout the European corridor and the New Silk Road to China.
Traxens and CFL multimodal (CFL) started their co-operation with a pilot project at the end of 2018, when CFL fitted Traxens Box devices on flat wagons travelling between European destinations. As this initial trial was successful, it was extended earlier this year to over 20 wagons delivering cargo to more distant European destinations. In April 2019 Traxens’ rail freight telematics technology was then tested on wagons travelling to China.
As part of it digitalization strategy, CFL aims to streamline train preparation operations through automation, including digital brake testing. Traxens’ Digital Freight Train® solutions can consolidate, secure and accelerate brake safety testing. This testing system can bring a number of benefits:
- Thirty minutes saved on standard reallocation processes to improve robustness or optimize loading
- Continuous monitoring of the brake system after departure, with real-time alerts for the train driver to prevent a flat wheel
- Improved safety and working conditions for shunting and ground operators who perform brake tests
- Can be used solely by the train driver instead of two agents — reducing operating costs and improving agility and quality of the whole system
- In the longer term, it will allow the interconnection of operators systems to improve interoperability and international trade, leading to better global efficiency of rail freight
Traxens’ solution provides comprehensive, precise and timely data about cargo by tracking wagons in transit anywhere in the world. Traxens’ technology brings improved efficiency and security, greater transparency and enhanced asset utilization thanks to improved wagons and goods tracking, geolocalisation and mileage monitoring.
The Traxens Box is straightforward to install within a few minutes whether on the customers’ sites, at railway terminals or workshops; it can be adapted to any type of wagon.
“As an outcome of our joint pilot project, we are delighted that CFL multimodal decided to extend its use of our bespoke IoT technology in its rail freight operations to China,” said Florence Delalande, rail business unit director at Traxens. “This shows the potential of our technology for all rail and intermodal freight businesses, as the shipping industry shifts towards a digital future.”
“Traxens’ rail freight solution helps our operations by enabling the monitoring of assets and their surroundings, which significantly improves operational efficiency,” said Marc Valette, innovation director at CFL multimodal. “The technology used by Traxens, enabling the local interconnection of different devices without wiring, opens up new opportunities in train condition and composition monitoring. This is a huge opportunity to improve operations and service effectiveness in rail. It will allow the connection of different elements of the train ecosystem in the future, providing transparent and accurate information, improving the quality of service and information delivered to clients.”
This agreement with CFL Multimodal is the latest development for Traxens in the rail sector. Traxens has already started cooperations with other key players in the industry, such as SNCF (the French national railway company). In cooperation with SNCF Logistics, Traxens developed the Digital Freight Train and its high value-added services for the benefit of the entire railway system, by turning conventional wagons into intelligent wagons in record time. It features geolocation, arrival notifications, consignment transport conditions and status monitoring, digital assistance for wagon management, predictive maintenance and more. Traxens offers a whole range of services for a safer, more modern, eco-friendly and more efficient freight railway system.
This year Traxens has already won several innovation awards for its Digital Freight Train project.
About CFL Multimodal
CFL multimodal is a logistics service
provider, covering the entire logistics chain. With 12 companies in six
European countries, CFL multimodal and its sister company CFL cargo
offer a broad and customised service portfolio: combined and
conventional rail freight, wagon maintenance and repairs, customs
clearance, as well as forwarding and logistics services. In Luxembourg,
the activities of CFL multimodal are organised around the intermodal
terminal of Bettembourg-Dudelange on the Eurohub South Logistics Park.
Located on the Rail Freight Corridor 2 (North Sea-Mediterranean) and at
the crossroads of major transport routes, the terminal is ideally
positioned as an international hub for the consolidation of multimodal
transport flows across Europe and beyond. With a total yearly capacity
of 600,000 units and equipped with the latest technology in terms of
security and surveillance, the intermodal terminal is connected by
combined train shuttles to the main ports and industrial regions.
www.cfl-mm.lu
ABOUT TRAXENS
Traxens generates, collects, consolidates,
enriches and transforms logistics asset data into actionable insight for
its clients in the maritime, rail and supply chain industries.
The
company’s breakthrough Internet-of-Big-Things technology provides
comprehensive, real-time information for managing logistics assets
anywhere in the world. Traxens’ solutions digitally transform
multi-modal supply chains, enabling customers to reduce costs, optimize
investments, comply with environmental regulations and deliver premium
services to their customers. Traxens’ IoT solution received the Frost &
Sullivan’s Technology Leadership Award in 2019.
www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005138/en/
Contact:
PRESS: Géraldine Saunière DIRECTOR OF COMMUNICATIONS Mail: g.sauniere@traxens.com Tel: +33 695 915 899
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
